Onivyde Too Expensive For NICE, Despite Dearth Of Pancreatic Cancer Drugs
Executive Summary
NICE has not recommended Shire's Onivyde in draft guidance as it is not cost effective, the HTA body for England and Wales said. The pancreatic cancer treatment has also struggled to make its mark on the US market where it is being commercialized by Merrimack Pharmaceuticals.
You may also be interested in...
Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde
Ipsen's new CEO David Meek has conducted the French company's biggest ever deal by acquiring Onivyde for pancreatic cancer from Merrimack Pharmaceuticals, and believes Ipsen will turn Onivyde's fortunes around.
Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks
CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.